Table 2. Clinical and laboratory parameters adversely impacting overall survival in 889 patients with primary myelodysplastic syndromes stratified by the absolute lymphocyte count (ALC subnormal vs ALC normal; ALC<1.2 × 109/l vs ALC (1.2–2.9) × 109/l).
| Variables | Univariate analysis, HR (95% CI) P-value | Multivariate analysis P-value (ALC subnormal vs ALC normal) | Multivariate analysis P-value (ALC<1.2 × 109/l vs ALC (1.2–2.9) × 109/l) |
|---|---|---|---|
| Older age (years) | <0.0001 | <0.0001 | <0.0001 |
| Gender (male) | <0.0001 | 0.01 | 0.02 |
| Lower hemoglobin, g/dl | <0.0001 | ||
| Hemoglobin <10 g/dl | <0.0001 | <0.0001 | <0.0001 |
| Lower leukocyte count, × 109/l | 0.1 | ||
| Lower platelet count, × 109/l | <0.0001 | ||
| Platelet count <100 × 109/l | <0.0001 | 0.004 | 0.003 |
| Absolute neutrophil count<0.8 × 109/l | 0.0002 | 0.3 | 0.3 |
| Increased circulating blasts % | <0.0001 | 0.003 | 0.002 |
| Increased bone marrow blast % | <0.0001 | <0.0001 | <0.0001 |
| IPSS-R, cytogenetic risk group | <0.0001 | <0.0001 | <0.0001 |
| IPSS-R, risk category | <0.0001 | ||
| Lower absolute lymphocyte count × 109/l | 0.01 | ||
| Absolute lymphocyte count, subnormal vs normal range | 1.3 (1.1–1.5) 0.001 | 0.1 | |
| Absolute lymphocyte count <1.2 × 109/l vs (1.2–2.9) × 109/l | 1.3 (1.2–1.6) 0.0002 | 0.06 |
Abbreviations: ALC, absolute lymphocyte count; CI, confidence interval; HR, hazard ratio; IPSS-R, Revised International Prognostic Scoring System. Reference normal range: ALC 0.9–2.9 × 109/l.
ALC <1.2 × 109/l, median value of ALC in our cohort of 889 patients with primary MDS. The bold values here denote the P-values that were found be significant on the analysis.